Table 4.

Odds ratios (95% confidence interval) for cardiovascular (coronary heart disease or stroke) events in relation to achieved (6-month in-trial) and median reductions in LDL-c and C-reactive protein

	Cases/controls	Model 1	P-value	Model 2	P-value	Model 3	P-value
		Target lipid or C-reactive protein concentration
Lipid
Placebo	89/232	1 (ref.)		1 (ref.)		1 (ref.)
Atorvastatin
LDL ≥2.1 mmol/La	44/126	0.97 (0.64, 1.46)	0.87	1.09 (0.70, 1.67)	0.71	1.10 (0.69, 1.76)	0.68
LDL <2.1 mmol/La	23/140	0.45 (0.27, 0.73)	0.001	0.45 (0.27, 0.76)	0.003	0.45 (0.27, 0.77)	0.003
LDL <2.1 vs. ≥2.1 mmol/L		0.40 (0.22, 0.71	0.002	0.41 (0.23, 0.74)	0.003	0.41 (0.22, 0.75)	0.004
C-reactive protein
Placebo	93/245	1 (ref.)		1 (ref.)		1 (ref.)
Atorvastatin
C-reactive protein ≥1.83 mg/La	41/137	0.86 (0.58, 1.29)	0.47	0.83 (0.54, 1.27)	0.39	0.82 (0.52, 1.28)	0.38
C-reactive protein <1.83 mg/La	32/140	0.61 (0.39, 0.94)	0.03	0.71 (0.45, 1.12)	0.14	0.70 (0.44, 1.13)	0.15
C-reactive protein <1.83 vs. ≥1.83 mg/L		0.70 (0.43, 1.16)	0.17	0.86 (0.50, 1.46)	0.56	0.86 (0.49, 1.51)	0.60

Model 1: unadjusted. Model 2: adjusted for baseline LDL cholesterol and log_ebaseline C-reactive protein. Model 3: current smoking status, diabetes mellitus, randomized BP treatment (atenolol/amlodipine), left ventricular hypertrophy, baseline SBP, HDL-cholesterol, BMI, log_e-glucose, family history of CHD, creatinine, educational attainment, baseline LDL-c or total cholesterol, and log_e baseline C-reactive protein.

^aMedian LDL and C-reactive protein concentrations in the atorvastatin group.